Clinical Trials List
2022-02-04 - 2025-06-13
Phase III
Recruiting3
ICD-10E85.0
Non-neuropathic heredofamilial amyloidosis
ICD-10E85.1
Neuropathic heredofamilial amyloidosis
ICD-10E85.2
Heredofamilial amyloidosis, unspecified
ICD-10E85.3
Secondary systemic amyloidosis
ICD-10E85.4
Organ-limited amyloidosis
ICD-10E85.8
Other amyloidosis
ICD-10E85.9
Amyloidosis, unspecified
ICD-9277.3
Amyloidosis
-
Trial Applicant
Pharmaceutical Research Associates Taiwan Inc.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Liang-Tsai Hsiao Division of Hematology & Oncology
- Ting-An Lin Division of Hematology & Oncology
- 郭泠 Division of Cardiovascular Diseases
- Chia-Jen Liu Division of Hematology & Oncology
- 陳玟均 Division of Hematology & Oncology
- Sheng-Hsuan Chien Division of Hematology & Oncology
- Jyh-Pyng Gau 無
- Hao-Yuan Wang Division of Hematology & Oncology
- Wen-Chung Yu Division of Cardiovascular Diseases
- Po-Shen Ko Division of Hematology & Oncology
- 蔡淳光 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- MING YAO Division of General Internal Medicine
- Sheng-chieh Chou Division of General Internal Medicine
- Wen-Chien Chou Division of General Internal Medicine
- 蔡承烜 Division of General Internal Medicine
- 田豐銘 Division of General Internal Medicine
- HSIN-AN HOU Division of General Internal Medicine
- Shang-Yi Huang Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
12 participants
-
Global
220 participants
